Brief: Initial Phase 1 Dose Escalation Data For Oric-533 In Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity And Strong Safety Profile Supporting Potential For Combination Development

ORIC Pharmaceuticals

11/12/2023 17:51

Oric Pharmaceuticals Inc  ORIC.O :
    * INITIAL PHASE 1 DOSE ESCALATION DATA FOR ORIC-533 IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA DEMONSTRATES CLINICAL
ACTIVITY AND STRONG SAFETY PROFILE SUPPORTING POTENTIAL FOR
COMBINATION DEVELOPMENT
    * ORIC PHARMACEUTICALS INC - COMPANY TO PURSUE STRATEGIC
PARTNERSHIP FOR COMBINATION STUDIES, RESULTING IN EXTENSION OF
CASH RUNWAY INTO 2026
    * ORIC PHARMACEUTICALS- CLEAN SAFETY PROFILE WITH ONLY GRADE
1 AND
2 TREATMENT RELATED ADVERSE EVENTS AND NO DOSE LIMITING
TOXICITIES OR DOSE REDUCTIONS
    * ORIC PHARMACEUTICALS INC - INTENDS TO COMPLETE DOSE
ESCALATION
FOR ORIC-533 IN Q1 OF 2024

Source text for Eikon:  ID:nGNX6QN7RQ 
Further company coverage:  ORIC.O